Forbion Capital Partners logo

Forbion Capital Partners

Europe, Noord-Holland, The Netherlands, Naarden

Description

Forbion Capital Partners is a private equity and venture capital firm for making investments in buyouts.

Investor Profile

Forbion Capital Partners has made 155 investments, with 21 in the past 12 months and 46% as lead.

Stage Focus

  • Series B (32%)
  • Series A (26%)
  • Series C (13%)
  • Series D (10%)
  • Seed (7%)
  • Series Unknown (5%)
  • Post Ipo Equity (4%)
  • Series F (2%)
  • Private Equity (2%)
  • Series E (1%)

Country Focus

  • United States (35%)
  • United Kingdom (17%)
  • The Netherlands (12%)
  • Germany (10%)
  • Switzerland (6%)
  • Canada (5%)
  • Denmark (3%)
  • Ireland (3%)
  • France (2%)
  • Belgium (2%)

Industry Focus

  • Biotechnology
  • Health Care
  • Medical
  • Therapeutics
  • Pharmaceutical
  • Biopharma
  • Genetics
  • Life Science
  • Health Diagnostics
  • Medical Device
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Forbion Capital Partners frequently co-invest with?

OrbiMed
North America, New York, United States, New York
Co-Investments: 11
Novartis Venture Fund
Europe, Basel-Stadt, Switzerland, Basel
Co-Investments: 12
Ysios Capital
Europe, Pais Vasco, Spain, San Sebastian
Co-Investments: 10
Atlas Venture
North America, Massachusetts, United States, Cambridge
Co-Investments: 9
RA Capital Management
North America, Massachusetts, United States, Boston
Co-Investments: 11
Andera Partners
Europe, Ile-de-France, France, Paris
Co-Investments: 10
BioGeneration Ventures
Europe, Noord-Holland, The Netherlands, Naarden
Co-Investments: 17
Novo Holdings
Europe, Hovedstaden, Denmark, Hellerup
Co-Investments: 11
Sofinnova Partners
Europe, Ile-de-France, France, Paris
Co-Investments: 11
Gilde Healthcare
Europe, Utrecht, The Netherlands, Utrecht
Co-Investments: 13

Which angels does Forbion Capital Partners often collaborate with?

PT
North America, California, United States, San Francisco
Shared Deals: 1
NB
Europe, Basel-Stadt, Switzerland, Basel
Shared Deals: 1

What are some of recent deals done by Forbion Capital Partners?

Verdiva Bio

London, England, United Kingdom

Verdiva Bio creates cutting-edge treatments that improve results for patients with obesity and cardiometabolic diseases.

BiotechnologyHealth CareMedical
Series AJan 9, 2025
Amount Raised: $411,000,000
Numab

Wadenswil, Zurich, Switzerland

Numab is a biotechnology company that offers antibody-based therapeutics for the treatment of severe diseases.

BiopharmaBiotechnologyHealth CareHealth DiagnosticsLife ScienceMedicalTherapeutics
Series CJan 9, 2025
Amount Raised: $54,939,501
Orbis Medicines

Frederiksberg, Hovedstaden, Denmark

Orbis Medicines is a novel macrocyclic chemistry and computational platform for oral macrocycle drug discovery.

Health CareMedicalPharmaceuticalTherapeutics
Series AJan 6, 2025
Amount Raised: $93,200,023
Noema Pharma

Basel, Basel-Stadt, Switzerland

Noema Pharma is a biotech company that develops therapies to address disabling symptoms in conditions of the brain and nervous system.

BiotechnologyMedicalPharmaceutical
Series BDec 11, 2024
Amount Raised: $30,567,953
Citryll

Oss, Noord-Brabant, The Netherlands

Citryll is a developer of pharmaceutical drugs used to treat autoimmune and other human diseases.

BiopharmaBiotechnologyMedicalMedical DeviceNeuroscience
Series BDec 9, 2024
Amount Raised: $89,720,936
SynOx Therapeutics

Dublin, Dublin, Ireland

SynOx Therapeutics is a biotechnology research company that focused on developing the treatment of diffuse tenosynovial giant cell tumors.

BiotechnologyMedicalTherapeutics
Series BOct 30, 2024
Amount Raised: $92,000,000
enGene

Vancouver, British Columbia, Canada

enGene is a biotechnology company develops treatment for mucosal diseases through inducing therapeutic proteins of harmful proteins.

BiotechnologyDiabetesGeneticsHealth Care
Post Ipo EquityOct 25, 2024
Amount Raised: $43,188,771
Purespring Therapeutics

London, England, United Kingdom

Purespring Therapeutics is a gene therapy company that provides treatments for different kidney diseases.

BiotechnologyMedicalTherapeutics
Series BOct 9, 2024
Amount Raised: $104,529,935
LOQUS23 THERAPEUTICS

London, England, United Kingdom

LoQus23 is a DDF-formed company focussing on targeting DNA damage repair pathways to treat Huntington’s disease.

Biotechnology
Series AOct 2, 2024
Amount Raised: $46,420,022
NOVAMEAT

Barcelona, Catalonia, Spain

NOVAMEAT develops cutting-edge technological solutions to feed the planet’s growing population with plant-based foods.

Alternative ProteinFood and BeverageFood ProcessingPlant-Based Foods
Series ASep 12, 2024
Amount Raised: $19,277,557